Ibex Investors’s Standard BioTools LAB Stock Holding History

Ibex Investors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,188	Closed	-$175K	–	103
2019 Q1	$175K	Buy	+13,188	New	+$139K	0.02%	55

Other funds holding LAB

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ibex Investors's LAB Position: Q2 2019 in Review

Ibex Investors sold out of Standard BioTools (LAB) in Q2 2019, closing a stake of 13,188 shares — an estimated $175K sold.

Ibex Investors first reported a position in LAB in Q1 2019 and held it in 1 quarter. The position peaked at $175K in Q1 2019. 135 funds tracked by Wall St. Rank hold LAB as of Q2 2019.

Ibex Investors reported no remaining Standard BioTools position as of Q2 2019 after selling out during the quarter.
Ibex Investors sold 13,188 Standard BioTools shares in Q2 2019, an estimated $175K.
Ibex Investors first reported a position in Standard BioTools in Q1 2019 and held it in 1 quarter.
Ibex Investors's Standard BioTools position peaked at $175K in Q1 2019.
135 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2019.

Based on Ibex Investors's 13F filing for Q2 2019, filed 29 Jul 2019.